Acrivon Therapeutics, Inc. (ACRV)

ACRV Biotech / Pharma

BiotechSign Signal Grade

F
Signal Grade
32.5/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
25
Dilution Risk
59
Clinical Activity
42
Short Interest
50

Pipeline Overview

Therapeutic Focus
Biotech / Pharmasrc

Clinical Trial Activity

3
Clinical Trials
(ClinicalTrials.gov aggregate)
1 Phase 1, 3 Phase 2
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
13.6 months
Cash Runway Estimate
59/100
Dilution Score
40Warrant Risk
40Convertible Risk
96Offering Ability

Dilution score: 59/100 (HIGH), 13.6 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

10.70%
Float Shorted
11.4
Days to Cover
MODERATE
Squeeze Risk
+3.9%
SI Change
STABLE
Trend
1,804,674
Shares Short

Short interest: 10.7% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Evidence and freshness

Record counts and statuses were computed on 2026-11-21. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.

PDUFA / FDA dates 0 No records
No upcoming FDA decision date found in the company's SEC filings
SEC 8-K filing
Clinical trials 3 Current
Updated within the last 14 days
ClinicalTrials.gov
Registry queried: Nov 16, 2026 · ingested Nov 16, 2026
Insider activity 1 Current
Updated within the last 10 days
SEC EDGAR Form 4
Window ends: Nov 21, 2026 · ingested Nov 21, 2026
Dilution risk 1 Derived
Derived score calculated from SEC data, not a raw record
DilutionWatch score (derived from SEC filings)
source date not recorded · ingested Nov 20, 2026
Short interest 1 Current
Updated within the last 21 days
FINRA short interest
source date not recorded · ingested Nov 20, 2026
Publications 5 Current
Updated within the last 30 days
PubMed
source date not recorded · ingested Nov 20, 2026

How the signal grade is calculated

The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.

What drives this company's 32.5/100 (grade F):

  • Clinical trials: signal score 0.42, weight used 49%, 20.2 points
  • Dilution risk: signal score 0.59, weight used 16%, 9.2 points
  • Short interest: signal score 0.50, weight used 6%, 2.9 points
  • Publications: signal score 0.25, weight used 1%, 0.2 points
  • Insider buying (Form 4): signal score 0.00, weight used 29%, 0.0 points

Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Acrivon Therapeutics, Inc..

Full ACRV Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.